Impairments of haemostasis and therapeutic management in patients with COVID-19
The lack of prior immunity to SARS-CoV-2 coronavirus (COVID-19) infection has led to pandemic, where there is no certain management, regarding the complications of this viral illness. The lungs are the target organ for COVID-19 and patients develop acute lung injury that may progress to respiratory and multiorgan failure. Recent data shows the presence of diffuse bilateral pulmonary inflammation in COVID-19 infection. It is associated with a specific pulmonary vasculopathy, defined as pulmonary intravascular coagulopathy (PIC) that is distinct from disseminated intravascular coagulopathy (DIC). The coagulopathy in the early stages of COVID-19 is characterized by initial elevation of D-dimer and fibrin/fibrinogen degradation products, while abnormalities in prothrombin time, partial thromboplastin time and platelet counts are uncommon. That is why screening of D-dimer and fibrinogen levels, are mandatory. COVID-19-associated coagulopathy should be treated, following the guidelines for thromboembolic prophylaxis. Although D-dimer is a marker of mortality, current data does not show routine application of anticoagulants, unless otherwise clinically indicated. Bleeding in COVID-19 is uncommon, even when a laboratory constellation for DIC is present. However, if it occurs, standard guidelines for DIC management should be followed..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Българска кардиология - 26(2020), 2, Seite 40-45 |
| Sprache: |
Bulgarisch ; Englisch |
|---|
| Beteiligte Personen: |
Zheina Cherneva [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Anticoagulat |
|---|
| doi: |
10.3897/bgcardio.26.e54113 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ04778461X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ04778461X | ||
| 003 | DE-627 | ||
| 005 | 20240414104952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||bul c | ||
| 024 | 7 | |a 10.3897/bgcardio.26.e54113 |2 doi | |
| 035 | |a (DE-627)DOAJ04778461X | ||
| 035 | |a (DE-599)DOAJ31269f2f644c4110aef5acff711e077c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a bul |a eng | ||
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a Zheina Cherneva |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impairments of haemostasis and therapeutic management in patients with COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The lack of prior immunity to SARS-CoV-2 coronavirus (COVID-19) infection has led to pandemic, where there is no certain management, regarding the complications of this viral illness. The lungs are the target organ for COVID-19 and patients develop acute lung injury that may progress to respiratory and multiorgan failure. Recent data shows the presence of diffuse bilateral pulmonary inflammation in COVID-19 infection. It is associated with a specific pulmonary vasculopathy, defined as pulmonary intravascular coagulopathy (PIC) that is distinct from disseminated intravascular coagulopathy (DIC). The coagulopathy in the early stages of COVID-19 is characterized by initial elevation of D-dimer and fibrin/fibrinogen degradation products, while abnormalities in prothrombin time, partial thromboplastin time and platelet counts are uncommon. That is why screening of D-dimer and fibrinogen levels, are mandatory. COVID-19-associated coagulopathy should be treated, following the guidelines for thromboembolic prophylaxis. Although D-dimer is a marker of mortality, current data does not show routine application of anticoagulants, unless otherwise clinically indicated. Bleeding in COVID-19 is uncommon, even when a laboratory constellation for DIC is present. However, if it occurs, standard guidelines for DIC management should be followed. | ||
| 650 | 4 | |a coagulopathy | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a anticoagulat | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 700 | 0 | |a Radostina Cherneva |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Българска кардиология |d Pensoft Publishers, 2020 |g 26(2020), 2, Seite 40-45 |w (DE-627)DOAJ000148261 |x 26831015 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2020 |g number:2 |g pages:40-45 |
| 856 | 4 | 0 | |u https://doi.org/10.3897/bgcardio.26.e54113 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/31269f2f644c4110aef5acff711e077c |z kostenfrei |
| 856 | 4 | 0 | |u https://journal.bgcardio.org/article/54113/download/pdf/ |z kostenfrei |
| 856 | 4 | 0 | |u https://journal.bgcardio.org/article/54113/download/xml/ |z kostenfrei |
| 856 | 4 | 0 | |u https://journal.bgcardio.org/article/54113/ |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2683-1015 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2020 |e 2 |h 40-45 | ||